The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma
High-grade serous ovarian carcinoma (HGSOC) is the deadliest of gynecological cancers due to its high recurrence rate and acquired chemoresistance. RAS/MEK/ERK pathway activation is linked to cell proliferation and therapeutic resistance, but the role of MEK1/2-ERK1/2 pathway in HGSOC is poorly inve...
Main Authors: | Mikhail S. Chesnokov, Imran Khan, Yeonjung Park, Jessica Ezell, Geeta Mehta, Abdelrahman Yousif, Linda J. Hong, Ronald J. Buckanovich, Akimasa Takahashi, Ilana Chefetz |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/6/1369 |
Similar Items
-
Response to re-challenge of a MEK inhibitor in a patient with recurrent low-grade serous carcinoma of the peritoneum
by: David M. Gershenson, et al.
Published: (2020-11-01) -
The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway
by: Juri Ogishima, et al.
Published: (2018-12-01) -
Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
by: Bengt Tholander, et al.
Published: (2020-10-01) -
Isotretinoin for the treatment of severe acneiform eruptions associated with the MEK inhibitor trametinib
by: Marco Caruana, MD, et al.
Published: (2020-10-01) -
Digital pathology-based study of cell- and tissue-level morphologic features in serous borderline ovarian tumor and high-grade serous ovarian cancer
by: Jun Jiang, et al.
Published: (2021-01-01)